Aquestive Therapeutics shares are trading higher after the company released topline PK data from the self-administration study of Anaphylm, which met primary endpoints with comparable PK whether administered by subjects or HCPs. The final OAS challenge study is enrolling, and a pre-NDA meeting is anticipated by the end of Q3 2024.
Portfolio Pulse from Benzinga Newsdesk
Aquestive Therapeutics shares are trading higher after the company released positive topline PK data from the self-administration study of Anaphylm, meeting primary endpoints. The final OAS challenge study is enrolling, and a pre-NDA meeting is expected by the end of Q3 2024.
July 26, 2024 | 6:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aquestive Therapeutics shares are trading higher following the release of positive topline PK data from the self-administration study of Anaphylm, which met primary endpoints. The final OAS challenge study is enrolling, and a pre-NDA meeting is anticipated by the end of Q3 2024.
The positive topline PK data meeting primary endpoints is a significant milestone for Aquestive Therapeutics, indicating potential future success for Anaphylm. The ongoing enrollment of the final OAS challenge study and the anticipated pre-NDA meeting by Q3 2024 further support a positive outlook, likely driving the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100